scholarly journals Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

2014 ◽  
Vol 32 (4) ◽  
pp. 356-363 ◽  
Author(s):  
E-Chiang Lee ◽  
Qi Liang ◽  
Hanif Ali ◽  
Luke Bayliss ◽  
Alastair Beasley ◽  
...  
Keyword(s):  
Therapeutic Antibody ◽  
Mouse Immunoglobulin ◽  
Antibody Discovery

scholarly journals ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery

mAbs ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 516-531 ◽  
Author(s):  
Philippe Valadon ◽  
Sonia M. Pérez-Tapia ◽  
Renae S. Nelson ◽  
Omar U. Guzmán-Bringas ◽  
Hugo I. Arrieta-Oliva ◽  
...  
Keyword(s):  
Therapeutic Antibody ◽  
Antibody Discovery ◽  
Antibody Libraries

The Art of Therapeutic Antibody Discovery: Finding Them One Cell at a Time

2019 ◽  
pp. 1-22
Author(s):  
Touyana Semenova ◽  
Richard Witas ◽  
Brianna L. Schroeder ◽  
Katherine Bohn ◽  
Alexandria Voigt ◽  
...  
Keyword(s):  
Therapeutic Antibody ◽  
Antibody Discovery

scholarly journals The role of phage display in therapeutic antibody discovery

2014 ◽  
Vol 26 (12) ◽  
pp. 649-657 ◽  
Author(s):  
C. E. Z. Chan ◽  
A. P. C. Lim ◽  
P. A. MacAry ◽  
B. J. Hanson
Keyword(s):  
Phage Display ◽  
Therapeutic Antibody ◽  
Antibody Discovery

scholarly journals Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

2021 ◽  
Author(s):  
Andrea R Shiakolas ◽  
Nicole Johnson ◽  
Kevin J Kramer ◽  
Naveenchandra Suryadevara ◽  
Daniel Wrapp ◽  
...  
Keyword(s):  
High Throughput ◽  
Neutralizing Antibodies ◽  
High Throughput Sequencing ◽  
Therapeutic Antibody ◽  
Sequencing Platform ◽  
Large Numbers ◽  
Ligand Interactions ◽  
Antibody Discovery ◽  
Small Set

SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. Here, we show that incorporating antibody-ligand blocking as part of LIBRA-seq, the high-throughput sequencing platform for antibody discovery, results in efficient identification of ultra-potent neutralizing antibodies against SARS-CoV-2. LIBRA-seq with ligand blocking is a general platform for functional antibody discovery targeting the disruption of antigen-ligand interactions.

Sign in / Sign up

Export Citation Format

Share Document